EUCTR2014-005153-39-LT进行中（未招募）1 期
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients with Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control with Insulin Therapy
exicon Pharmaceuticals, Inc.0 个研究点目标入组 750 人开始时间: 2015年3月31日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Patient has given written informed consent to participate in the study in accordance with local regulations
- •2) Adult patients 18 years and older with a diagnosis of T1D made at least 1 year prior to informed consent
- •3) Patients are being treated with insulin or insulin analog delivered via CSII or MDI where the method of insulin delivery has not changed from CSII to MDI or vice-versa in the 3 months prior to the Screening Visit
- •4) At the Screening Visit, A1C must be 7.0% to 11.0%, inclusive
- •5) Must be willing and able to perform SMBG and complete the study diary as required per protocol
- •6) Females of childbearing potential must use an adequate method of contraception to avoid pregnancy throughout the duration of the study and for 30 days after the last dose of study drug. Females of childbearing potential include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal. Postmenopause is defined as no menses for =12 months without another cause. For females with questionable menopausal history (eg, irregular menstrual periods and age >40 years) a documented serum follicle-stimulating hormone (FSH) level must be =30 mIU/mL.
- •7) Females of childbearing potential must have a negative serum or urine pregnancy test prior to the start of study drug. In the case of positive urine pregnancy testing, a negative serum sample for pregnancy testing, to confirm that the patient is not pregnant, must be obtained prior to start of study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 375
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 375
排除标准
- •1) Therapies and/or medications
- •a) Use of antidiabetic agent other than insulin or insulin analog at the time of screening
- •b) Any prior exposure to LX4211
- •c) Use of SGLT inhibitors within 8 weeks prior to Screening
- •d) Chronic systemic corticosteroid use, defined as any dose of systemic corticosteroid taken for more than 4 consecutive weeks within the 6 months prior to the Screening Visit.
- •2) Diabetes-related conditions:
- •a) Type 2 diabetes mellitus, or severely uncontrolled diabetes mellitus as determined by the Investigator
- •b) History of severe hypoglycemic event within 1 month prior to the Screening Visit.
- •c) History of DKA within 1 month prior to Screening visit, or more than 2 episodes within 6 months prior to the Screening visit
- •d) History of nonketotic hyperosmolar state within 6 months prior to the Screening Visit
- •3) Laboratory Results
- •a) Estimated glomerular filtration rate <45 mL/min/1.73 m2 at Screening, as determined by the 4 variable Modification of Diet in Renal Disease (MDRD) equation
- •b) Fasting triglycerides >600 mg/dL.
- •c) Abnormal liver function at Screening defined as any of the following: aspartate aminotransferase (AST) >2X upper limit of the normal reference range (ULN), alanine aminotransferase (ALT) >2X ULN, serum total bilirubin (TB) >1.5X ULN.
- •d) Screening beta-hydroxy butyrate (BHB) >0.6 mmol/L.
- •4) Reproductive status:
- •a) Females who are pregnant or breastfeeding or intend to be during the course of the study
- •5) Gastrointestinal/hepatic:
- •a) By known history, serologic evidence of current infectious liver disease (hepatitis A, B, or C), including antihepatitis A virus (immunoglobulin M), hepatitis B surface antigen, or antihepatitis C virus.
- •b) Difficulty swallowing such that the patient cannot take the study drug
- •c) History of pancreatitis within 12 months of screening
- •a) Initiation of chronic dialysis within 30 days prior to the Screening Visit or expected to occur within 180 days after the Screening Visit
- •b) Renal disease that required treatment with immunosuppressive therapy, or a history of dialysis or renal transplant
- •c) History of hereditary glucose-galactose malabsorption or primary renal glucosuria
- •7) Cardiovascular:
- •a) New York Heart Association Class III or IV heart failure within 3 months prior to Screening Visit
- •b) Hypertensive urgency or emergency within 30 days prior to randomization.
- •c) Patients with unstable/symptomatic or life-threatening arrhythmia or heart block.
- •d) Patient has had any of the following within 3 months prior to the Screening Visit:
- •i. Hospitalization due to unstable angina
- •iii. Coronary artery bypass graft or percutaneous transluminal coronary angioplasty
- •iv. Transient ischemic attack or significant cerebrovascular disease
- •8) Hematologic:
- •a) History of hemoglobinopathies (sickle cell anemia, thalassemia major, sideroblastic anemia) or other disorder that may interfere with A1C determination
- •b) Donation or loss of >400 mL of blood or blood product(s) within 8 weeks prior to Screening
- •9) Immune system: Known severe immunocompromised status, including, but not limited to, patients who have undergone organ transplantation.
- •10) Malignancy or active treatment for malignancy within 5 years prior to the Screening Visit.
- •11) Current eating disorder or increase or decrease of weight within the 12 weeks prior to Screening by more than 10%
- •12) Known allergies, hypersensitivity, or intolerance to LX4211 or any inactive com
研究者
相似试验
招募中
1 期
A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).CTIS2023-506669-70-00Alexion Pharmaceuticals Inc.982
进行中（未招募）
1 期
Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCCResectable high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC)MedDRA version: 20.0 Level: PT Classification code 10041823 Term: Squamous cell carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001974-76-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.570
进行中（未招募）
1 期
Phase 3 Study of Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)Recurrent, Platinum-Sensitive Ovarian CancerMedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005099-21-NOMersana Therapeutics, Inc.581
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to study the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents = 6 to <18 years of ageAcute Migraine (with or without aura)MedDRA version: 20.0Level: PTClassification code 10052787Term: Migraine without auraSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10027607Term: Migraine with auraSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: HLTClassification code 10027603Term: Migraine headachesSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-005246-15-PLPfizer Inc.640
进行中（未招募）
1 期
Combining chemotherapy with either the medication entospletinib or a placebo for adults with acute myeloid leukemia that has a nucleophosmin-1 abnormalityMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864Acute Myeloid LeukemiaEUCTR2021-000761-33-PLKronos Bio, Inc.180